## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Braunstein Scott						2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) C/O PAC	st) (First) (Middle) D PACIRA PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 07/13/2015									X below	,	y & (	Other ( below) Corp. Dev	specify
5 SYLVAN WAY, SUITE 300 (Street) PARSIPPANY NJ 07054						4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(City) (State) (Zip)														reiso				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Execution Date,			Code (Ins	Transaction Disp Code (Instr. and		surities Acquired (A) sed Of (D) (Instr. 3, )			r 5. Amo Securit Benefic Owned Follow	ties Fo cially (D In		Ownership m: Direct or irect (I) tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amoun	Amount (A) or (D)		Price	Report Transa	Reported Transaction(s) (Instr. 3 and 4)			(1150.4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transact Code (In 8)	ion of		6. Date Exer Expiration I (Month/Day		d 7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		. 3	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership		
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	or	ount nber res					
Employee Stock Option (Right to Buy)	\$67.11	07/13/2015			A		75,000		(1)	07/	/13/2025	Common Stock	75,	000	\$0	75,000		D	

Explanation of Responses:

1. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

## <u>/s/ Kristen Williams, Attorney-</u> 07/15/2015 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.